ReviewJournal of cancer research and clinical oncology2026
Therapeutic progress in leptomeningeal metastasis from EGFR mutant non-small cell lung cancer: a clinical medicine review.
Review in Journal of cancer research and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Leptomeningeal metastasis in patients with Epidermal Growth Factor Receptor-mutant non-small cell lung cancer carries a dismal prognosis and is associated with profound neurological morbidity. Historically, therapeutic efficacy has been severely limited, leading to poor overall survival. This review aims to synthesize the recent, albeit incremental, advances in the multidisciplinary management of this devastating complication. We delve into the evolving landscape of treatment modalities, with a particular focus on the latest generation of tyrosine kinase inhibitors and their superior central nervous system penetration. The roles of conventional approaches, including radiotherapy (both whole-brain and focal) for symptom palliation and tumor control, and intrathecal chemotherapy, are critically re-evaluated in the modern context. Furthermore, we explore the rationale and early evidence for novel combination strategies. A significant portion of our analysis is dedicated to evaluating the pharmacodynamic mechanisms of action, optimizing dosing strategies, and interpreting clinical outcomes from key trials and real-world evidence. Central to the discussion are the persistent challenges of adequate blood-brain barrier penetration, the emergence of therapeutic resistance, and the management of overlapping toxicities. We also address the parallel progress in diagnostic neuro-imaging and cerebrospinal fluid liquid biopsies, which are enhancing early detection and disease monitoring. Finally, this review outlines future research directions, emphasizing the need for randomized controlled trials and a deeper understanding of the tumor microenvironment to foster a paradigm shift in the care of patients with leptomeningeal metastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.